Contribution of the Lung to the Genesis of Cheyne-Stokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time

Alberto Giannoni, MD, PhD,* Francesco Gentile, MD,* Alessandro Navari, MSc; Chiara Borrelli, MD; Gianluca Mirizzi, MD; Giosuè Catapano, MD, PhD; Giuseppe Vergaro, MD, PhD; Francesco Grotti, MS; Monica Betta, MSc; Massimo F. Piepoli, MD, PhD; Darrel P. Francis, PhD; Claudio Passino, MD; Michele Emdin, MD, PhD

Background—The contribution of the lung or the plant gain (PG; ie, change in blood gases per unit change in ventilation) to Cheyne-Stokes respiration (CSR) in heart failure has only been hypothesized by mathematical models, but never been directly evaluated.

Methods and Results—Twenty patients with systolic heart failure (age, 72.4±6.4 years; left ventricular ejection fraction, 31.5±5.8%), 10 with relevant CSR (24-hour apnea-hypopnea index [AHI] ≥10 events/h) and 10 without (AHI <10 events/h) at 24-hour cardiorespiratory monitoring underwent evaluation of chemoreflex gain (CG) to hypoxia ([CGO2]) and hypercapnia ([CGCO2]) by rebreathing technique, lung-to-finger circulation time, and PG assessment through a visual system. PG test was feasible and reproducible (intraclass correlation coefficient, 0.98; 95% CI, 0.91–0.99); the best-fitting curve to express the PG was a hyperbola (R²=0.98). Patients with CSR showed increased PG, [CGCO2] (but not [CGO2]), and lung-to-finger circulation time, compared with patients without CSR (all P<0.05). PG was the only predictor of the daytime AHI (R²=0.56, P=0.01) and together with the [CGCO2] also predicted the nighttime AHI (R²=0.81, P=0.0003) and the 24-hour AHI (R²=0.71, P=0.001). Lung-to-finger circulation time was the only predictor of CSR cycle length (R²=0.82, P=0.00006).

Conclusions—PG is a powerful contributor of CSR and should be evaluated together with the CG and circulation time to individualize treatments aimed at stabilizing breathing in heart failure. (J Am Heart Assoc. 2019;8:e012419. DOI: 10.1161/JAHA.119.012419.)

Key Words: chemoreceptor • chronic heart failure • circulation • lung • sleep apnea

Cheyne-Stokes respiration (CSR) is a form of periodic breathing characterized by alternating phases of hyperventilation and central apneas, typical of severe chronic conditions, such as congestive heart failure (HF). This breathing pattern results in numerous repetitive fluctuations in blood gases and hemodynamics, causes chronic sympathetic overactivation, impedes exercise capacity, precipitates ventricular arrhythmias, and increases mortality in HF. Current treatments of CSR have rarely considered its complex pathogenesis in HF or tried to interfere with its pathophysiological triggers, with consequent disappointing results of major clinical trials based on positive pressure ventilation.

In the past decades, different mathematical models have been proposed to describe the pathophysiology of CSR. The overall accepted hypothesis is that the respiratory system could be seen as a closed-loop system, with a certain transit time in the feedback loop. The loop gain (LG) can be defined as the ratio between the power of the response to a disturbance/the disturbance itself. Generally, the system reacts vigorously to each perturbation with a high LG, and with weaker effect when the LG is low. The main determinants of LG are the controller gain and the plant gain (PG).
The controller within the respiratory system is represented by the chemoreflex gain (CG; change in ventilation per unit change in P\textsubscript{CO\textsubscript{2}} or P\textsubscript{O\textsubscript{2}}), whereas the PG is represented by the lungs (change in P\textsubscript{CO\textsubscript{2}} or P\textsubscript{O\textsubscript{2}} per unit change in ventilation). The connection between the controller and the plant is represented by the blood circulating between the lung and the chemoreceptors. If the LG is <1, the response to any respiratory disturbance does not overshoot by more than the size of the original disturbance, so that ventilation slowly returns to steady state. Conversely, if LG is ≥1, any respiratory disturbance produces a response, which is even larger, leading to growing cycles of oscillation.

With these premises, the chemoreflex has been thoroughly evaluated in patients with HF and CSR\textsuperscript{15–17}. Increased CG is associated with CSR\textsuperscript{16,17}, adrenergic overactivation\textsuperscript{16,17} and arrhythmias \textsuperscript{16,17} and has independent prognostic significance in HF. However, there is extensive overlap in CG between patients with and without CSR\textsuperscript{15}.

Although a few studies have also evaluated the role of circulation time (Ct), showing mainly an association with CSR cycle length rather than CSR severity, the role of PG has never been investigated.

We hypothesized that full evaluation of the global LG, including the CG, the PG, and the Ct, might increase the capability to correctly predict respiratory stability and to design future rational and effective strategies to stabilize breathing, on the basis of tailored pathophysiological approaches acting on CSR triggers. Therefore, we developed a novel method for direct evaluation of PG, and we tested it in healthy subjects and in patients with HF with and without CSR, beyond the evaluation of both the CG and the Ct.

## Methods

The data that support the findings of this study are available from the corresponding author on reasonable request.

## CG Assessment

Chemoreflex sensitivity was assessed using the rebreathing technique, as previously explained\textsuperscript{17,18}. In summary, subjects were examined in standardized conditions, while seated and connected to a rebreathing circuit through a mouthpiece. ECG, airway flow, and respiratory gases were recorded continuously through a breath-by-breath gas analyzer (Vmax;
Sensormedics, CA), and SaO2 was recorded through a pulse oximeter (SET Radical; Masimo).

A 4-minute baseline recording was performed during spontaneous breathing. Then, the CGO2 and the CGCO2 were performed in a random order.

In the CGO2, an isocapnic hypoxia trial was done (from resting SaO2 values to 70%–80%, according to individual tolerance), with end-tidal CO2 (etCO2) kept constant through a scrubbing circuit; the CGO2 was then expressed by the linear regression slope between minute ventilation and SaO2.

In the CGCO2, a progressive normoxic hypercapnic trial was done (from resting etCO2 values until 50 mm Hg or an increase >10 mm Hg from the basal values, according to individual tolerance), with inspired partial pressure of oxygen kept at the baseline value by adding oxygen to the circuit; the CGCO2 was expressed by the linear regression slope between minute ventilation and the end-tidal pressure of CO2.

**PG Assessment**

To estimate the PG, we developed a new test to guide and monitor patient’s breath-by-breath imposed variations in minute ventilation and consequent changes in etCO2.

It was possible to refer the etCO2 to the invasive arterial measure, excluding from the study pulmonary diseases with different alveolar emptying constants.

To enable subjects to change ventilation to a predetermined value, the subject’s signal from the pneumotachograph (Vmax) was monitored online by a dedicated computer, running custom-designed software. The system was programmed to change subject’s ventilation as a percentage of resting ventilation, increasing/decreasing tidal volume and respiratory rate by the same proportion.

The system displayed a moving bar controlled by the subject’s inspiration, which should reach a tidal volume target.

**Figure 1.** Schematic representation of plant gain assessment. A, The patient/software interface showing patient’s inspiratory bar, target tidal volume (TV), and respiratory rate (RR) dynamic cursor. B, TV target is moved away from resting TV and RR cursor changes velocity across the different respiratory maneuvers, to obtain a prefixed percentage change in baseline ventilation. C, The postprocessing software interface allows us to reliably select a 20-second plateau in the end-tidal CO2 (etCO2) signal, following imposed changes in minute ventilation (Vt).
at a respiratory rate rhythm given by a dynamic cursor (Figure 1A and Video S1).

The study subject was first trained to familiarize with the software interface. After a 5-minute baseline recording to obtain resting ventilation and etCO₂, each subject was asked to perform 5 maneuvers in random order: 2 hypoventilation maneuvers (a -20% and -10% decrease from baseline ventilation) and 3 hyperventilation maneuvers (a 20%, 40%, 60% increase from baseline ventilation) (Figure 1B).

Each step was maintained for at least 5 minutes, until a plateau in etCO₂ had been achieved and maintained for ≥ 20 seconds. Each step was separated by the following one by 5 minutes of recovery (Figure 1B). Data were then analyzed (Figure 1C).

Table 1. Clinical Features of Patients With HF With or Without CSR

| Feature                  | Patients With HF | Patients With HF With 24-h AHI <10 events/h | Patients With HF With 24-h AHI ≥10 events/h |
|--------------------------|------------------|---------------------------------------------|---------------------------------------------|
| Total no.                | 20               | 10                                          | 10                                          |
| Age, y                   | 72.4±6.4         | 71.4±7.3                                    | 73.4±5.6                                    |
| Men                      | 19 (95)          | 9 (90)                                      | 10 (100)                                    |
| BMI, kg/m²               | 26.3±3.3         | 26.1±4.1                                    | 26.6±2.5                                    |
| BSA, m²                  | 1.97±0.17        | 1.97±0.18                                   | 1.98±0.16                                   |
| Plasma creatinine, mg/dL | 1.12±0.37        | 1.17±0.48                                   | 1.07±0.22                                   |
| eGFR, mL/min per 1.73 m² | 67.7±20.6        | 67±23.5                                     | 66.5±18.1                                   |
| Hemoglobin, g/dL         | 13.8±1.3         | 13.9±0.8                                    | 13.4±1.7                                    |
| Ischemic/idiopathic      | 9/11 (45/55)     | 5/5 (50/50)                                 | 4/6 (40/60)                                 |
| NYHA class I/II/III      | 6/12/2 (30/60/10)| 4/5/1 (40/50/10)                            | 2/7/1 (20/70/10)                            |
| Atrial fibrillation      | 11 (55)          | 5 (50)                                      | 6 (60)                                      |
| Ejection fraction, %     | 31.5±5.8         | 32.9±6.1                                    | 30.2±5.5                                    |
| Diastolic dis function II–III | 10 (50)      | 5 (50)                                      | 5 (50)                                      |
| Moderate-to-severe MR    | 8 (40)           | 3 (30)                                      | 5 (50)                                      |
| sPAP, mm Hg              | 40.4±10.0        | 41.9±6.4                                    | 39.2±12.4                                   |
| FAC, %                   | 40.1±9.0         | 36.3±7.4                                    | 43.9±9.5                                    |
| HS-troponin T, ng/L      | 18.4 (10.2–26.4) | 13.7 (8.7–25.3)                             | 21.5 (16.6–31.5)                            |
| Norepinephrine, ng/L     | 431.5 (326.8–690.5) | 400 (290.5–513.0)                       | 561 (352.0–804.8)                           |
| Renin, μU/mL             | 39.1 (11.7–81.6) | 42.1 (14.4–95.2)                            | 30.4 (4.1–77.0)                             |
| Aldosterone, ng/L        | 82.9 (56.2–127.0) | 82.3 (55.1–82.3)                            | 92.5 (67.0–127.0)                           |
| BNP, ng/L                | 240.0 (142.0–659.0) | 219.0 (80.0–303.0)                      | 449.5 (164.3–824.0)                         |
| NT-proBNP, ng/L          | 981 (484.8–2353.5) | 580 (265.0–1187.8)                      | 1340 (772.3–3494.3)*                        |
| β Blockers               | 20 (100)         | 10 (100)                                    | 10 (100)                                    |
| ACEI-ARB                 | 14 (70)          | 7 (70)                                      | 7 (70)                                      |
| ARNI                     | 6 (30)           | 3 (30)                                      | 3 (30)                                      |
| MRA                      | 17 (85)          | 7 (70)                                      | 10 (100)                                    |
| Furosemide               | 11 (55)          | 6 (60)                                      | 5 (50)                                      |
| Digoxin                  | 1 (5)            | 1 (10)                                      | 0 (0)                                       |
| CRT-D                    | 7 (35)           | 4 (40)                                      | 3 (30)                                      |
| CRT-P                    | 1 (5)            | 0 (0)                                       | 1 (10)                                      |
| ICD                      | 1 (5)            | 0 (0)                                       | 1 (10)                                      |

Data are given as mean±SD, number (percentage), or median (interquartile range). ACEI indicates angiotensin-converting enzyme inhibitor; AHI, apnea-hypopnea index; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BMI, body mass index; BNP, brain natriuretic peptide; BSA, body surface area; CRT-D, cardiac resynchronization therapy-defibrillator; CRT-P, CRT-pacemaker; CSR, Cheyne-Stokes respiration; eGFR, estimated glomerular filtration rate by Modification of Diet in Renal Disease equation; FAC, fractional area change; HF, heart failure; HS, high sensitivity; ICD, implantable cardioverter-defibrillator; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; sPAP, systolic pulmonary artery pressure.

*P<0.05 vs patients with HF with 24-h AHI <10 events/h.
Table 2. Respiratory Profile of Patients With HF With or Without CSR

| Variable                        | Patients With HF | Patients With HF With 24-h AHI <10 events/h | Patients With HF With 24-h AHI ≥10 events/h |
|---------------------------------|------------------|----------------------------------------------|--------------------------------------------|
| Daytime AHI, events/h           | 5 (2.0–14.5)     | 2 (0.8–5.3)                                  | 13 (4.8–27.0)*                             |
| Nighttime AHI, events/h         | 18 (5–31)        | 5 (2.8–11.8)                                 | 31 (22.8–36.8)*                            |
| 24-h AHI, events/h              | 9 (4.3–17.8)     | 4.5 (2.8–7.0)                                | 19.5 (15.8–31.3)*                          |
| Daytime CAI, events/h           | 0 (0–3)          | 0 (0–0)                                      | 3 (1.8–18.8)*                              |
| Nighttime CAI, events/h         | 2.5 (0–14.5)     | 0 (0–1)                                      | 14 (7.0–21.3)*                             |
| 24-h CAI, events/h              | 1.5 (0–8)        | 0 (0–0)                                      | 7.5 (3.8–17.3)*                            |
| Daytime OAI, events/h           | 0                | 0                                            | 0 (0–1)                                    |
| Nighttime OAI, events/h         | 1 (0–2)          | 0 (0–2)                                      | 2 (0.8–2.5)                                |
| 24-h OAI, events/h              | 0.5 (0–1)        | 0 (0–1)                                      | 1 (0–1.3)                                  |
| Cycle length, s                 | 59.8±10.7        | 53.1±7.7                                     | 66.5±9.1*                                  |
| Apnea length, s                 | 20.3±3.8         | 17.4±2.9                                     | 23.2±1.8*                                  |
| Hyperpnea length, s             | 39.6±7.9         | 35.8±6.2                                     | 43.4±7.8*                                  |
| SaO2 min, %                     | 86.1±3.3         | 86.7±3.8                                     | 85.5±2.7                                   |
| T-90, min                       | 5 (2–12)         | 4 (0.8–11)                                   | 9 (2–13)*                                  |

Data are given as median (interquartile range) or mean±SD. AHI indicates apnea-hypopnea index; CAI, central apnea index; CSR, Cheyne-Stokes respiration; HF, heart failure; OAI, obstructive apnea index; SaO2, oxygen saturation; T-90, time spent with SaO2 <90%.

*P<0.05 vs patients with HF with 24-h AHI <10 events/h.

PG was calculated as the ratio between the variances of etCO2 and minute ventilation across the different respiratory maneuvers (Equation 1).

\[
PG = \frac{\sigma^2(\text{etCO}_2)}{\sigma^2(\text{ventilation})}
\] (1)

The PG repeatability was assessed in 5 volunteers on 2 consecutive days.

Statistical Analysis

Statistical analysis was performed using SPSS (IBM Statistics, version 25.0; 2017). A 2-tailed \(P<0.05\) was considered significant. Values were expressed as mean±SD or median and interquartile range, according to a normal or skewed distribution, evaluated by Kolmogorov-Smirnov test; or as percentages for categorical data. The \(\chi^2\) goodness-of-fit test for modified hyperbolic function was used to verify the shape of the PG relationship, using GraphPad Prism, version 7.04 for Windows.

For quantitative variables, comparison between 2 groups was performed using Mann-Whitney \(U\) test, whereas comparison among >2 groups was performed using the Kruskal-Wallis test, with Dunn post hoc correction. For qualitative variables, a \(\chi^2\) or Fisher exact test was used.

Before regression analysis, variables with a skewed distribution were logarithmically corrected. Univariable and multivariable linear regression analyses were implemented to identify predictors of CSR severity and CSR cycle length (dependent variables), entering the CG, the PG, and the LFCt (independent variables) into the multivariable regression only if they resulted in predictors at univariable analysis with \(P<0.05\); multicollinearity was excluded by calculation of variance inflation factor, considering a low risk of multicollinearity if the variance inflation factor was <10. Repeatability was measured with the intraclass correlation coefficient and its 95% confidence interval.

Results

The clinical characteristics of the HF population are shown in Table 1. Patients were mainly men, with mild symptoms (90% in New York Heart Association class I/II) confirming clinical stability, despite moderate-severe left ventricular systolic and diastolic dysfunction and presence of relevant mitral regurgitation and atrial fibrillation in 50% and 40%, respectively. All patients were receiving optimal medical and device treatment. According to matching criteria, patients and healthy controls were similar ages (72.4±6.4 versus 69.2±2.7 years; \(P=0.14\)), had a similar proportion of men (95% versus 90%; \(P=0.28\)), and had a similar body mass index (26.3±3.3 versus 25.9±3.7 kg/m\(^2\); \(P=0.76\)) and body surface area (1.97±0.17 versus 1.90±0.18 m\(^2\); \(P=0.10\)).

Patients with CSR showed a higher plasma value of NT-proBNP (N-terminal pro-B-type natriuretic peptide; \(P=0.03\)) compared with patients without CSR (Table 1). No differences
in age, body mass index, body surface area, New York Heart Association class, renal function, left ventricular systolic and diastolic function, systolic pulmonary pressure, and right ventricular function were observed between patients with or without CSR (Table 1).

Because of patient allocation, patients with CSR showed increased AHI and CAI at daytime, nighttime, and over 24 hours, as well as increased CSR cycle length, apnea and hyperpnea length, and time spent with SaO₂ <90%, whereas no difference was found in the obstructive apnea index (Table 2).

### Chemoreflex Sensitivity, PG, and Ct

Patients with CSR showed higher CGCO₂ compared with both patients without CSR (P=0.02) and healthy controls (P=0.01,

### Table 3. CG, PG, and Ct Measurement in the Study Population

| Variable          | Healthy Controls | Patients With HF With 24-h AHI <10 events/h | Patients With HF With 24-h AHI ≥10 events/h |
|-------------------|------------------|---------------------------------------------|---------------------------------------------|
| CG                |                  |                                             |                                             |
| Baseline VE, L/min| 11.9±2.0         | 11.9±2.4                                    | 11.3±2.4                                    |
| Baseline etCO₂, mm Hg | 33.6±3.4      | 31.9±3.2                                    | 31.8±3.4                                    |
| Baseline SaO₂, %  | 95.7±1.1         | 95.9±1.6                                    | 95.4±1.5                                    |
| CG₀₀, etCO₂, mm Hg| 32.5±5.7         | 31.5±3.1                                    | 31.4±3.5                                    |
| CG₀₀, SaO₂, %     | 78.2±1.4         | 81.5±4.8                                    | 81.6±4.7                                    |
| CG₀₀, VE, L/min   | 19.6±8.0         | 17.6±5.1                                    | 22.6±7.7                                    |
| CG₀₀, 1/min per %SaO₂ | 0.19 (0.06–0.69) | 0.29 (0.14–0.60)                            | 0.42 (0.23–0.67)                            |
| CGCO₂ etCO₂, mm Hg| 47.3±4.6         | 47.5±3.1                                    | 48.0±3.6                                    |
| CGCO₂, SaO₂, %    | 95.8±1.2         | 95.5±1.4                                    | 96.3±1.2                                    |
| CGCO₂, VE, L/min  | 24.1±9.1         | 26.2±5.4                                    | 36.1±11.1†                                   |
| CGCO₂, L/min per mm Hg | 0.82 (0.15–1.13) | 0.89 (0.48–1.01)                            | 1.45 (0.99–2.26)*†                          |
| PG                |                  |                                             |                                             |
| Baseline VE, L/min| 11.9±2.0         | 11.9±2.4                                    | 11.3±2.4                                    |
| -10% VE, L/min    | 10.3±3.9         | 10.6±2.2                                    | 9.9±2.2                                     |
| -20% VE, L/min    | 9.5±2.0          | 9.8±2.4                                     | 8.6±1.8                                     |
| 20% VE, L/min     | 14.2±2.0         | 14.7±3.1                                    | 13.9±2.4                                    |
| 40% VE, L/min     | 17.3±2.3         | 17.3±3.2                                    | 16.2±2.1                                    |
| 60% VE, L/min     | 20.3±2.6         | 19.9±3.7                                    | 18.9±2.9                                    |
| Baseline etCO₂, mm Hg | 33.8±3.5      | 31.4±3.4                                    | 32.2±3.1                                    |
| -10% etCO₂, mm Hg | 34.2±3.3         | 32.7±3.2                                    | 33.7±2.9                                    |
| -20% etCO₂, mm Hg | 35.2±3.4         | 32.8±3.0                                    | 35.3±3.2                                    |
| 20% etCO₂, mm Hg  | 28.7±3.3         | 28.1±3.1                                    | 27.9±3.6                                    |
| 40% etCO₂, mm Hg  | 26.6±3.4         | 25.2±2.5                                    | 24.5±2.3                                    |
| 60% etCO₂, mm Hg  | 24.2±3.1         | 22.3±2.5                                    | 20.9±2.4†                                   |
| PG, mm Hg/L per min | 1.15 (0.83–2.06) | 1.37 (1.09–1.88)                            | 2.19 (1.44–2.81)*†                          |
| Ct                |                  |                                             |                                             |
| Daytime LFct, s   | ...              | 26.7±2.8                                    | 33.4±6.9‡                                   |
| Nighttime LFct, s | ...              | 26.1±3.1                                    | 32.9±6.4*                                   |
| 24-h LFct, s      | ...              | 26.4±3.6                                    | 34.0±6.2‡                                   |

Data are given as mean±SD or median (interquartile range). CG₀₀ and CGCO₂ are the values recorded and averaged in the last 10 seconds of the CG₀₀ and CGCO₂ maneuvers. AHI indicates apnea-hypopnea index; CG, chemoreflex gain; CG₀₀, CG to hypercapnia; CGCO₂, CG to hypoxia; Ct, circulation time; etCO₂, end-tidal CO₂; HF, heart failure; LFct, lung-to-finger Ct; PG, plant gain; SaO₂, oxygen saturation; VE, minute ventilation.

*P<0.05 vs HF with 24-hour AHI <10 events/h.

†P<0.05 vs healthy controls.

‡P<0.01 vs HF with 24-hour AHI <10 events/h.
Conversely, no difference was found in CGO2 among the different groups (Table 3 and Figure 3). No difference in both CGO2 and CGCO2 was found between patients without CSR and healthy controls. Both healthy subjects and patients with HF were able to perform the PG test correctly (Table 3), with little deviation from target ventilation (3.1±1.4% in the whole population, 2.7±2.9% in healthy subjects, 2.9±1.4% in those with HF without CSR, and 3.6±1.1% in those with HF with CSR). The PG test showed a high repeatability: intraclass correlation coefficient, 0.98 (95% CI, 0.91–0.99). The best-fitting curve to express the relationship between induced changes in etCO2 and changes in ventilation was a hyperbola ($R^2=0.99$ for patients without CSR and healthy controls, and $R^2=0.98$ for patients with CSR) (Figure 4A).

PG was higher in patients with CSR than in patients without CSR ($P=0.02$) and healthy controls ($P=0.01$, Table 3 and Figure 4B). No difference in PG was found between patients without CSR and healthy controls. No significant difference in spirometry, lung diffusion, and blood gas analysis was found between patients with normal and increased PG, apart from a trend toward an increase in the forced expiratory volume in the first second ($P=0.06$) and in the total lung capacity (% predicted; $P=0.09$) in patients with increased PG (Table 4).

The 24-hour, daytime, and nighttime LFCt values were all increased in patients with CSR compared with patients without CSR (all $P<0.05$, Figure 5). No significant differences were observed in the LFCt calculated at different time windows (daytime, nighttime, and 24-hour period), within the same group of patients.

CGCO2 and LFCt were correlated ($q=0.64$, $P=0.004$), whereas no correlation was found between PG and CGCO2 or PG and LFCt.

### Prediction of CSR Severity and CSR Cycle Length

The univariable and multivariable predictors of CSR severity in patients with HF are shown in Table 5, whereas linear regression plots (for each CSR predictor) are shown in Figure 6.

At multivariable analysis, CGCO2 and PG were independent predictors of both the 24-hour AHI (Figure 7A) and the nighttime AHI (Figure 7B), whereas PG was the only predictor of CSR cycle length.
independent predictor of the daytime AHI (Figure 7C). LFCt was only a univariable predictor of nighttime AHI, but it lost its predictive value at multivariable analysis. Using CAI as the target variable, PG was the only predictor of 24-hour ($R^2 = 0.55$, $P = 0.01$) and daytime ($R^2 = 0.59$, $P = 0.006$) CAI, whereas CGCO2 was the only predictor of nighttime CAI ($R^2 = 0.56$, $P = 0.01$).

On the other hand, the LFCt was an independent predictor of CSR cycle length (Figure 8A), as well as of hyperventilation length (Figure 8B). Apnea length was predicted by both LFCt and the CGCO2, with LFCt remaining the only independent predictor at multivariable analysis (Figure 8C).

### Discussion

This was the first study to assess the PG in patients with HF with and without CSR. Assessing the PG, instead of only CG and the Ct, allowed us to comprehensively test the instability loop hypothesis (Figure 9).13 Higher CGCO2, PG, and Ct values were found in patients with CSR. Notably, both CG and PG were able to predict CSR severity during the 24-hour period and at nighttime, whereas only PG was able to predict CSR severity at daytime. Ct showed no role in CSR severity prediction, but was strongly related to CSR cycle length and to hyperventilation and apnea length.

### The Instability Loop Hypothesis

The pathophysiological characteristics of CSR in HF are complex and multifactorial. Despite much theoretical and experimental work, a thorough understanding of the mechanisms involved and their interactions has not been achieved. The strength of the pathophysiological model is key to guide experiments designed to challenge the model’s assumption and to provide optimal treatments for patients with a disease.32 On the other hand, if a treatment is not strongly pathophysiologically based and referred to a solid model, the randomized controlled trial is likely to fail, as happened to mask-based therapies based on positive airway pressure, derived from the treatment of obstructive apneas and applied to central apneas of HF.7,8

In this setting, a great contribution was provided by the use of mathematical models. Currently, the most accepted hypothesis is that the respiratory control system could be seen as a closed-loop system, constituted by a controller (ie, the chemoreflex) and the plant (ie, the lung), with a transit time in the feedback loop (ie, Ct). In principle, therefore, increased CG, increased PG, and increased Ct have theoretical potential to increase the global LG and cause CSR.

#### Testing the Instability Loop Hypothesis: CG

Alteration in the gain of the chemoreceptors has been well documented in both experimental and clinical settings.15–19 The original observation by Javaheri15 that CGCO2 was strongly correlated with CSR severity was later confirmed by different research groups.16–19,34 In the current study, the CGCO2 was again confirmed to play a key role in the prediction of CSR severity. By contrast, no significant difference in the CGCO2 was found between patients with or without CSR, highlighting once more that CO2, rather than hypoxia, is the main driver of ventilation, especially at night when ventilation is under chemical control. Recent lines of evidence have shown that in animals with HF, the CG remains high throughout the 24 hours, including the biological night, differently from healthy animals in which the CG is known to decrease during the inactive phase.35 This may also justify why the difference between the eupneic CO2 and the CO2 at anaerobic threshold is decreased at night in patients with HF and CSR compared with patients with stable breathing.36 The reasons for this persistent overactivity of the CG at night is still unknown, but key differences in the chronobiological characteristics of neurohormonal activity and in cardiac hemodynamics.

![Plant Gain and Cheyne-Stokes Respiration](image)
(decreased cardiac output and increased filling pressure), together with a decrease in cerebrovascular reactivity to increased CO₂ (decreased CO₂ washout from chemoreceptors), to at night might be involved.

Testing the Instability Loop Hypothesis: PG

Before this study, the PG had been only mathematically hypothesized and evaluated in a single study by Miyamoto et al in healthy volunteers, but not in patients with HF. Similar to Miyamoto et al, we also used a visual system to drive subjects during PG execution, but we performed shorter ventilatory maneuvers, to increase the feasibility in patients with HF. Moreover, we calculated the PG as a ratio between the variances of etCO₂ and ventilation, rather than using a linear slope obtained at the equilibrium set point, to more reliably express the PG behavior far from stationary conditions.

The feasibility of the test was demonstrated by the reassuringly small discrepancy (≤5%) between the target and recorded ventilation in each respiratory maneuver, not only in healthy subjects, but even in patients with HF with or without CSR. Furthermore, as predicted by mathematical models, the relationship between changes in ventilation and the resulting changes in etCO₂ fitted a hyperbola (R²=0.99 for patients without CSR and healthy controls, and R²=0.98 for patients with CSR).

Notably, we first observed that the PG is increased in patients with HF with CSR, being ≈60% higher than in patients with HF without CSR. Moreover, the PG was the only predictor of CSR severity at daytime, where the chemical control is overdriven by different stimuli, especially cortical influences. Furthermore, adding PG to CG resulted in a more accurate prediction of CSR severity at night (PG+CGCO₂ versus CGCO₂ alone R=0.61). To put into practice, this means that in patients with a high PG, whatever stimulus is able to change ventilation can make the system oscillate and cause CSR, such as exercise or a mental stress when the patient is awake or an arousal when the patient is sleeping. This should be accounted for when
Figure 5. Lung-to-finger circulation time (LFCt) in patients with and without Cheyne-Stokes respiration (CSR). The LFCt was increased in patients with heart failure (HF) with Cheyne-Stokes respiration (CSR) compared with patients without CSR, over the 24-hour period (A), at daytime (B), and at nighttime (C). AHI indicates apnea-hypopnea index.

Table 5. Univariable and Multivariable Models for Prediction of 24-Hour AHI, Nighttime AHI, and Daytime AHI

| Variable | Univariable Model | Multivariable Model | Multivariable Model |
|----------|------------------|---------------------|---------------------|
|          | Univariable Model | Multivariable Model | Multivariable Model |
|          | \(\beta\), Mean±SD | \(R\) | \(R^2\) | \(P\) Value | \(\beta\), Mean±SD | \(R\) | \(R^2\) | \(R^2\)-Penalized | \(P\) Value | VIF |
| Prediction of 24-h AHI | | | | | | | | | | |
| \(\text{CGCO}_2\) | 6.9±3.3 | 0.46 | 0.21 | 0.04 | 8.3±2.7 | 0.71 | 0.51 | 0.44 | 0.008 | 1.03 |
| \(\text{PG}\) | 8.3±3.1 | 0.54 | 0.29 | 0.02 | 8.9±2.9 | | | | | |
| \(\text{LFCt}\) | 0.7±0.4 | 0.38 | 0.14 | 0.10 | ... | | | | | |
| Prediction of nighttime AHI | | | | | | | | | | |
| \(\text{CGCO}_2\) | 11.4±3.7 | 0.61 | 0.36 | 0.007 | 10.4±3.3 | 0.81 | 0.65 | 0.57 | 0.007 | 1.24 |
| \(\text{PG}\) | 8.5±4.1 | 0.44 | 0.19 | 0.04 | 8.1±3.3 | | | | | |
| \(\text{LFCt}\) | 1.1±0.5 | 0.49 | 0.24 | 0.03 | ... | | | | | |
| Prediction of daytime AHI | | | | | | | | | | |
| \(\text{CGCO}_2\) | 3.9±3.4 | 0.26 | 0.07 | 0.29 | ... | | | | | |
| \(\text{PG}\) | 8.3±2.8 | 0.56 | 0.32 | 0.01 | | | | | | |
| \(\text{LFCt}\) | 0.41±0.38 | 0.25 | 0.06 | 0.29 | | | | | |

AHI indicates apnea-hypopnea index; \(\text{CGCO}_2\), chemoreflex gain to hypercapnia; LFCt, lung-to-finger circulation time; PG, plant gain; VIF, variance inflation factor.
designing and testing novel treatments aimed at stabilizing breathing.

Indeed, several therapeutic approaches have been thought to act on the PG to obtain ventilatory stability, such as CO₂ administration (by increasing lung CO₂ reserve), increase of death space (thus decreasing the washout of CO₂ from the lung), acetazolamide administration (causing a shift in the ventilatory equilibrium at a different set point), and positive pressure ventilation (by altering lung anatomical characteristics and/or mechanics). The PG was recently measured in patients with obstructive sleep apnea (n=8) and matched controls (n=7), by using a pseudorandom binary stimulation (63 breaths alternating between room air and 4% CO₂, switching frequencies of between 1 and 6 consecutive breaths of CO₂). No difference was found between patients with obstructive sleep apnea and controls, and no effect on positive pressure ventilation (by altering lung anatomical characteristics and/or mechanics). The PG was recently measured in patients with obstructive sleep apnea (n=8) and matched controls (n=7), by using a pseudorandom binary stimulation (63 breaths alternating between room air and 4% CO₂, switching frequencies of between 1 and 6 consecutive breaths of CO₂). No difference was found between patients with obstructive sleep apnea and controls, and no effect on

Figure 6. Linear regression plots relating loop gain components and Cheyne-Stokes respiration (CSR) severity in different time windows. Linear regression plots relating chemoreflex gain to hypercapnia (CGCO₂), plant gain (PG), and lung-to-finger (LF) circulation time (LFCt) with CSR severity, as expressed by the apnea-hypopnea index (AHI), over the 24-hour period (A), at nighttime (B), and at daytime (C).

DOI: 10.1161/JAHA.119.012419
the PG was observed after 6 week of continuous positive airway pressure treatment.

The main determinants of the PG remained still unknown. In contrast to the hypothesis that lung congestion and the gas-diffusion impairment may increase the PG, in our population, no significant difference in spirometry, lung diffusion, and blood gas analysis parameters was found between patients with high PG (PG above the median) and low PG (Table 4). The only exception was a trend toward an increase in forced expiratory volume in the first second \( (P=0.06) \) and total lung capacity \( (P=0.09) \) in patients with high PG. These results should be interpreted with caution, and further investigations in a larger population are needed to address this key pathophysiological issue.

**Testing the Instability Loop Hypothesis: \( \text{Ct} \)**

The pathophysiological role of \( \text{Ct} \) delay in determining respiratory instability was supposed by mathematical modeling \(^9\)–\(^{12}\) and experimentally demonstrated in dogs by Crowell and coworkers already in 1956.\(^{14}\) However, the increase in \( \text{Ct} \) needed to make ventilation unstable in anesthetized dogs\(^{14}\) was much higher (from 40 seconds to 5 minutes) than that observed in patients with HF.\(^{20}\) Subsequent studies in humans have highlighted that \( \text{Ct} \) delay seems to be mainly associated with CSR cycle length and hyperventilation length, rather than CSR onset or severity.\(^{20}\)

In our population and differently from previous studies, the LFCt, besides cycle length and hyperpnea length, also predicted the apnea duration. This difference may be

---

**Figure 7.** Regression plots showing predictors of Cheyne-Stokes respiration severity in different time windows. Chemoreflex gain to hypercapnia (\( \text{CGCO}_2 \)) and plant gain (PG) were independent predictors of apnea-hypopnea index (AHI) over the 24-hour period (A) and at nighttime (B), whereas only PG was an independent predictor of AHI at daytime (C).

**Figure 8.** Regression plots showing predictors of Cheyne-Stokes respiration (CSR) cycle and hyperpnea and apnea lengths. The lung-to-finger circulation time (LFCt) was the only independent predictor of CSR cycle length (A), hyperventilation length (B), and apnea length (C).
explained by the use of LFCt over the 24-hour period in place of the lung-to-ear Ct, evaluated only in phase 2 non–rapid eye movement sleep in the article by Hall et al,20 or by the higher number of patients with HF recruited in the current study. Both methods (LFCt and lung-to-ear Ct) were inversely correlated with cardiac output.20,28,29

**Study Limitations**

The PG test requires patient cooperation, and so it is unsuitable when there is marked physical and/or cognitive impairment. Nonetheless, in our population, the feasibility was 100%, even in patients with unstable breathing. Although the LFCt is only an estimation of the true Ct, it has the advantage of being measurable directly from cardiorespiratory monitoring. On the contrary, circulation time has no role in prediction of CSR severity, but it is associated with CSR cycle length. V\text{e}, minute ventilation.

The CG and the PG were only evaluated during the daytime, when the patient was awake, and this may decrease our capacity to predict the ventilatory behavior (stability/instability and CSR severity and length) throughout the 24 hours. Currently, there is no evidence in patients with HF about the potential changes in the CG and the PG from awake to sleep conditions. Although we can hypothesize that the CG would remain high at night in patients with unstable breathing, as observed in animals,35 the potential changes of the PG at night are less predictable. We believe that, at night, the change in body position may reduce lung volumes, and further potential influences on the PG may be also related to the typical rostral fluid shift of patients with HF.

Finally, the relatively small sample size of the study seems to hardly support the development of multivariable models. However, having used only 3 variables (independent variables; namely, the CG, the PG, and the LFCt) with a strong pathophysiological relationship with CSR severity and length (dependent variables), together with the lack of any relationships between the independent variables, apart from that observed between CG\text{CO}_2 and LFCt, has actually increased the power of analysis (in each multivariable regression model, the calculated power was always >98%). Furthermore, the variance inflation factor observed makes the risk of multicollinearity rather low.

**Conclusions and Perspectives**

Ct does not predict CSR severity, but it influences the CSR cycle and hyperpnea and apnea length. The PG can be easily measured in patients with HF and is increased in patients with HF presenting with unstable ventilation, as previously hypothesized by mathematical models. Its estimation may help in predicting the severity of CSR at daytime and in refining the prediction of CSR severity at nighttime, when evaluated together with the CG. Future treatment strategies should consider those triggers to tailor a rational and thus effective approach in individual patients with HF and CSR.

**Disclosures**

None.

**References**

1. Emdin MG, Giannoni A, Passino C. The Breathless Heart: Apneas in Heart Failure. Basel, Switzerland: Springer; 2017.
2. Floras JS. Sympathetic nervous system activation in human with heart failure: clinical implications of an updated model. J Am Coll Cardiol. 2009;54:375–385.
3. Andreas S, Clemens C, Sandholzer H, Figulla HR, Kreuzer H. Improvement of exercise capacity with treatment of Cheyne-Stokes respiration in patients with congestive heart failure. J Am Coll Cardiol. 1996;27:1486–1490.
4. Bitter T, Westerheide N, Prinz C, Hossain MS, Vogt J, Langer C, Horstkotte D, Oldenburg O. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J. 2011;32:61–74.
5. Oldenburg O, Wellmann B, Buchholz A, Bitter T, Fox H, Thiem U, Horstkotte D, Wegscheider K. Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients. Eur Heart J. 2016;37:1695–1703.
6. Emdin M, Mirizzi G, Giannoni A, Poletti R, Iudice G, Bramanti F, Passino C. Prognostic significance of central apneas throughout a 24-hour period in patients with heart failure. J Am Coll Cardiol. 2017;70:1351–1364.
7. Bradley TD, Logan AG, Kimmul R, Sérias F, Morrison D, Ferguson K, Belenkin I, Pfeifer M, Fletcham J, Hanly P, Smilovitch M, Tominson G, Floras JS; CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med. 2005;353:2025–2033.
8. Cowie MR, Woehrel H, Wegscheider K, Angermann C, d’Ortho MP, Erdmann E, Levy P, Simonds AK, Somers VK, Zannad F, Tschiescher H. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015;373:1095–1105.

9. Longobardo GS, Cherniack NS. Cheyne-Stokes breathing produced by a model of the human respiratory system. J Appl Physiol. 1986;21:1839.

10. Carley DW, Shannon DC. A minimal mathematical model of human periodic breathing. J Appl Physiol. 1988;65:1400–1409.

11. Khoo MCK. Determinants of ventilatory instability and variability. Respir Physiol. 2000;122:167–182.

12. Francis D, Willson K, Davies LC, Coats AJ, Piepoli M. Quantitative general theory for periodic breathing in chronic heart failure and its clinical implications. Circulation. 2000;102:2214–2221.

13. White DP. Pathogenesis of obstructive and central sleep apnea. Am J Respir Crit Care Med. 2005;172:1363–1370.

14. Crowell JW, Guyton AC, Moore JW. Basic oscillating mechanism of Cheyne-Stokes breathing. Am J Physiol. 1956;187:395–398.

15. Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Engl J Med. 1999;341:949–954.

16. Ponikowski P, Anker SD, Chua TP, Francis D, Bansai W, Poole-Wilson PA, Coats AJ, Piepoli M. Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity. Circulation. 1999;100:2418–2424.

17. Giannini A, Edmën M, Poletti R, Bramanti F, Ponfretta C, Piepoli M, Passino C. Clinical significance of chemosensitivity in chronic heart failure: influence on neurohumoral derangement, Cheyne-Stokes respiration and arrhythmias. Clin Sci (Lond). 2008;114:499–497.

18. Giannini A, Edmën M, Bramanti F, Ludic G, Francis DP, Barsotti A, Piepoli M, Passino C. Combined increased chemosensitivity to hypoxia and hypercapnia as a prognosticator in heart failure. Am J Cardiol. 2009;53:1975–1980.

19. Ponikowski P, Chua TP, Anker SD, Francis DP, Doehner W, Bansai W, Poole-Wilson PA, Piepoli MF, Coats AJ. Peripherial chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation. 2001;104:544–549.

20. Hall MJ, Xie A, Rutherford R, Ando S, Floras JS, Bradley TD. Cycle length of periodic breathing in patients with and without heart failure. Am J Respir Crit Care Med. 1996;154:376–381.

21. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Janicka EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, Van Der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–2200.

22. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Postma DS, Global Initiative for Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: NHLB/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276.

23. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Emane L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rischitz F, Rutten FH, Van Der Meer P. 2016 ESC guidelines for the diagnosis of heart failure in adults: an update on the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.

24. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2012;25:297–314.

25. Kernik LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie K, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685–713.

26. Edim EN, Passino C, Prondora C, Iervasi A, Rippoli A, Masini S, Zucchielli GC, Clerico A. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med. 2004;42:627–636.

27. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floros JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T, American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology; American Heart Association Stroke Council, American Heart Association Council on Cardiovascular Nursing; American College of Cardiology Foundation. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Cardiology, Stroke Council, and Council on Cardiovascular Nursing; in collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008;118:1080–1111.

28. Hosokawa K, Ando SI, Tohyama T, Kiyokawa T, Tanaka Y, Otsubo H, Nakamura R, Kadokami T, Fukuyama T. Estimation of nocturnal cardiac output by automated analysis of circulatory time derived from polysomnography. Int J Cardiol. 2015;181:14–16.

29. Kwon Y, van't Hof J, Roy SS, Bache RJ, Das G. A novel method for assessing cardiac output with the use of oxygen circulation time. J Card Fail. 2016;22:921–924.

30. Read DJ. A clinical method for assessing the ventilatory response to carbon dioxide. Australis Am Med 1967;16:20–32.

31. Rebuck A, Campbell E. A clinical method for assessing the ventilatory response to hypoxia. Am Rev Respir Dis. 1973;109:345–350.

32. Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–254.

33. Schultz HD, Marcus NJ, Del Rio R. Role of the carotid body chemoreflex in the pathophysiology of heart failure: a perspective from animal studies. Adv Exp Med Biol. 2015;860:167–185.

34. Solin P, Roebuck T, Johns DP, Walters EI, Naughton MT. Peripheral and central ventilatory responses in central sleep apnea with and without congestive heart failure. Am J Respir Crit Care Med. 2000;162:2194–2200.

35. Lewis R, Hackfort BT, Schultz HD. Chronic heart failure abolishes circadian rhythms in resting and chemoreflex breathing. Adv Exp Med Biol. 2018;1071:129–136.

36. Xie A, Skatrud JB, Poleus DS, Rahko PS, Dempsey JA. Apnea-hypopnea threshold for CO2 in patients with congestive heart failure. Am J Respir Crit Care Med. 2002;165:1245–1250.

37. Xie A, Skatrud JB, Barszi SR, Reichmuth K, Morgan BJ, Mont S, Dempsey JA. Influence of cerebral blood flow on breathing stability. J Appl Physiol (1985). 2009;106:850–856.

38. Miyamoto T, Nakahara H, Ueda S, Manabe K, Kawai E, Inagaki M, Kawada T, Sugimachi M. Periodic breathing in heart failure explained by dynamic and static properties of respiratory control. Clin Med Insights Cardiol. 2015;9:133–142.

39. Andreas S, Weidel K, Hagenah G, Heindl S. Treatment of Cheyne-Stokes respiration with nasal oxygen and carbon dioxide. Eur Respir J. 1999;12:414–419.

40. Giannini A, Baruah R, Willson K, Mebrate Y, Mayet J, Edmën M, Hughes AD, Manisty CH, Francis DP. Real-time dynamic carbon dioxide administration: a novel treatment strategy for stabilization of periodic breathing with potential application to central sleep apnea. J Am Coll Cardiol. 2010;56:1832–1837.

41. Khayat RN, Xie A, Patel AK, Kaminski A, Skatrud JB. Cardiorespiratory effects of added dead space in patients with heart failure and central sleep apnea. Chest. 2003;123:151–1560.

42. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med. 2006;173:234–237.

43. Fontana M, Edmën M, Giannini A, Luiche G, Baruah R, Passino C. Effect of acetazolamide on chemosensitivity, Cheyne-Stokes respiration, and response to effort in patients with heart failure. Am J Cardiol. 2011;107:1675–1680.

44. Deacon-Diaz NL, Sands SA, McEvoy RD, Catcheside PG. Daytime loop gain is elevated in obstructive sleep apnea but not reduced by CPAP treatment. J Appl Physiol. 2018;125:1490–1497.

45. Szollosi I, Thompson BR, Krum H, Kaye DM, Naughton MT. Impaired pulmonary diffusing capacity and hypoxia in heart failure correlates with central sleep apnea severity. Chest. 2008;134:67–72.